Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Cost-effectiveness and budget impact of obesity surgery in patients with type 2 diabetes in three European countries(II).

Anselmino M, Bammer T, Fernández Cebrián JM, Daoud F, Romagnoli G, Torres A.

Obes Surg. 2009 Nov;19(11):1542-9. doi: 10.1007/s11695-009-9946-z.

PMID:
19756896
2.

Cost-effectiveness and budget impact of obesity surgery in patients with type-2 diabetes in three European countries.

Ackroyd R, Mouiel J, Chevallier JM, Daoud F.

Obes Surg. 2006 Nov;16(11):1488-503.

PMID:
17132416
3.

Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes.

Abbatini F, Rizzello M, Casella G, Alessandri G, Capoccia D, Leonetti F, Basso N.

Surg Endosc. 2010 May;24(5):1005-10. doi: 10.1007/s00464-009-0715-9.

PMID:
19866235
4.

[Medicoeconomic evaluation of the treatment of morbid obesity by Swedish adjustable gastric banding (SAGB)].

Chevallier JM, Daoud F, Szwarcensztein K, Volcot MF, Rupprecht MF.

Ann Chir. 2006 Jan;131(1):12-21. French.

PMID:
16364230
5.

Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.

Tunis SL, Willis WD, Foos V.

Curr Med Res Opin. 2010 Jan;26(1):163-75. doi: 10.1185/03007990903429765.

PMID:
19919377
6.

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. doi: 10.1185/030079908X297295 .

PMID:
18400145
7.

Bariatric surgery for severely obese adolescents.

Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, Wolfe LG.

J Gastrointest Surg. 2003 Jan;7(1):102-7; discussion 107-8.

PMID:
12559191
8.

Gastric bypass is a cost-saving procedure: results from a comprehensive Markov model.

Faria GR, Preto JR, Costa-Maia J.

Obes Surg. 2013 Apr;23(4):460-6. doi: 10.1007/s11695-012-0816-8.

PMID:
23341033
9.

Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients.

Ikramuddin S, Klingman D, Swan T, Minshall ME.

Am J Manag Care. 2009 Sep;15(9):607-15.

10.

The cost-effectiveness of bariatric surgery.

Fang J.

Am J Gastroenterol. 2003 Sep;98(9):2097-8. Review.

PMID:
14499794
11.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
12.

Vertical banded gastroplasty versus adjustable gastric banding: prospective long-term follow-up study.

Miller K, Pump A, Hell E.

Surg Obes Relat Dis. 2007 Jan-Feb;3(1):84-90.

PMID:
17116427
13.

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.

PMID:
16800162
14.

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84. doi: 10.1185/03007990902869169 .

PMID:
19366302
15.

The impact of weight reduction surgery on health-care costs in morbidly obese patients.

Sampalis JS, Liberman M, Auger S, Christou NV.

Obes Surg. 2004 Aug;14(7):939-47.

PMID:
15329183
16.

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.

Lacey LA, Wolf A, O'shea D, Erny S, Ruof J.

Int J Obes (Lond). 2005 Aug;29(8):975-82.

PMID:
15852050
17.

Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis.

Keating CL, Dixon JB, Moodie ML, Peeters A, Bulfone L, Maglianno DJ, O'Brien PE.

Diabetes Care. 2009 Apr;32(4):567-74. doi: 10.2337/dc08-1749.

18.

Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study.

Coupaye M, Puchaux K, Bogard C, Msika S, Jouet P, Clerici C, Larger E, Ledoux S.

Obes Surg. 2009 Jan;19(1):56-65. doi: 10.1007/s11695-008-9571-2.

PMID:
18542847
19.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
20.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Curr Med Res Opin. 2007 Sep;23(9):2157-69. Review.

PMID:
17669232
Items per page

Supplemental Content

Support Center